Article Text

Download PDFPDF
895 The utility, safety and outcomes of ovarian tissue cryopreservation for gynecologic cancers: an analysis from a large fertility preservation program and systematic review of the literature
  1. Murat Erden1,
  2. Sonia Gayete-Lafuente1,
  3. Nazli Aylin Vural1,2 and
  4. Kutluk Oktay1
  1. 1Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, United States
  2. 2Department of Gynecological Oncology, Basaksehir Cam and Sakura State Hospital, Istanbul, Turkey


Introduction/Background Since its first transplant success in 2000 (Oktay-Karlikaya NEJM 2000), ovarian tissue cryopreservation (OTC) has been increasingly successful and no longer considered experimental. We sought to determine the utility of OTC in gynecological cancers as the experience is limited.

Methodology 100 OTC cases in our fertility preservation program (1997–2022) and those obtained from a systematic literature review were included in the analysis.

Results Our OTC indications included hematologic malignancies (39%), breast (15%), gynecological (12%), and other cancers (9%) and non-cancer (25%). For gynecological cancer, the median age at OTC was 29.5 years. Of those, 3 had endometrial cancer (endometroid type with stages 1A, 1B, and 3A), 2 cervical cancer (stage 2-adenocarcinoma, stage 1B-squamous), and 7 ovarian tumors (2 epithelial carcinoma, 1 teratoma, 1 yolk sac tumor, 1 dysgerminoma and 2 borderline). Of these, 1 returned for ovarian tissue transplantation (OTT), resulting in generation of 4 embryos. The patient is awaiting embryo transfer to a gestational carrier.

On systematic review, OTC and OTT rates for gynecological cancers were 7.1% and 13.08%, respectively (Figure-1A-B). Of all OTC, 178 were for gynecological cancers with OTT return rate of 5.6% (Figure-1C). The median age at OTC was 31 years and graft longevity was 32 months. Following ART, cumulative delivery rate was 40%/recipient (two deliveries in granulosa cell tumor and ovarian mucinous cancer, two miscarriages in ovarian borderline tumor and endometrial sarcoma, and no oocytes retrieved in one with cervical cancer). No cancer recurrence was reported after OTT in graft sites. In one case with granulosa cell tumor, diaphragmatic and pelvic brim metastases were resected along with graft during the C-section; the patient remained in complete remission.

Conclusion Though the return rate is low, OTC+OTT appears to be generally safe in gynecological cancer, resulting in live-births. However, OTC+OTT may carry a risk of metastasis in granulosa cell tumors.

Disclosures No disclosures.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.